Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 22,366 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 30, 2026, 8:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ginger.io Behavioral Health Study

NCT02491307
View directory record Official record
Conditions
Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Ginger.io Smartphone Application
Other
Lead sponsor
Community Health Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Meriden, Connecticut • Middletown, Connecticut • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 8:11 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Active for Life Assisted Living Feasibility and Acceptability Study

NCT04386434
View directory record Official record
Conditions
Sedentary Behavior
Interventions
Active for Life: Assisted Living
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Dietary Supplement in Subjects With Acid Reflux and/or Abdominal Bloating/Distention and GI Symptoms

NCT06808867
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Dietary Supplement with Active Ingredient Blend
Dietary Supplement
Lead sponsor
Olly, PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Not applicable Interventional Results available

Cognitive Rehabilitation in Post-COVID-19 Syndrome

NCT06136871
View directory record Official record
Conditions
Post-COVID-19 Syndrome
Interventions
CO-OP Procedures, Inactive Control Group
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Barbershop Talk: HIV Prevention for African American Heterosexual Men

NCT01980771
View directory record Official record
Conditions
HIV
Interventions
BTWB intervention, Cancer prevention and screening
Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 30, 2026, 8:11 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Terminated Phase 2 Interventional Results available

Mepolizumab in Episodic Angioedema With Eosinophilia

NCT04128371
View directory record Official record
Conditions
Eosinophilia, Angioedema
Interventions
mepolizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 30, 2026, 8:11 AM EDT
Active, not recruiting Not applicable Interventional

An Intervention to Enhance Well-Being in Trauma Exposed New Mothers

NCT05474534
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Dissociation, Maternal Care Patterns, Infant Behavior, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation
Interventions
Neurofeedback (MUSE 2)
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 8:11 AM EDT
Recruiting Not applicable Interventional

Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain

NCT07708064
View directory record Official record
Conditions
Overweight or Obesity
Interventions
JITAI Combined with psychological intervention, Active Control
Behavioral
Lead sponsor
ORI Community and Evaluation Services
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cough and Swallow Rehab Following Stroke

NCT01907321
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Expiratory muscle strength training, Placebo expiratory training, Measures performed on all subjects, Pulmonary function test, Fluoroscopic swallow study
Behavioral · Drug · Radiation
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Not applicable Interventional

ReCoUPS: Post-Concussion Patient Reports

NCT04499937
View directory record Official record
Conditions
Brain Concussion, Head Injury
Interventions
Streak incentive, Loss-based incentive, Flat-fee control status quo condition, Flat-Fitbit control status quo condition
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)

NCT01506453
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Neuropathy, Neuropathic Pain
Interventions
gabapentin, placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

NCT02477839
View directory record Official record
Conditions
Epilepsy With Partial-onset Seizures
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 47 Months
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Tampa, Florida • Henderson, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 30, 2026, 8:11 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301
View directory record Official record
Conditions
Well-Being, Psychological, Psychedelic Experiences
Interventions
Psilocybin, Saline Placebo, Clonidine
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 30, 2026, 8:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

NCT07136181
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Drug
Lead sponsor
Novelwise Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 30, 2026, 8:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

RTMS Targets Neural Circuits for Smoking Cessation

NCT04903028
View directory record Official record
Conditions
Tobacco Use, Cigarette Smoking
Interventions
Sham rTMS, Active rTMS 10 Hz DLPFC
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

NCT06574828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 30, 2026, 8:11 AM EDT
Completed Phase 4 Interventional

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

NCT00315367
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 30, 2026, 8:11 AM EDT